Resveratrol promotes the sensitivity of small-cell lung cancer H446 cells to cisplatin by regulating intrinsic apoptosis

WANGPING LI1*, YUN SHI1*, RUIXUAN WANG1, LEI PAN1, LIJIE MA1,2 and FAGUANG JIN1

1Department of Respiration, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038;
2Department of Respiration, Chengdu Military General Hospital, Chengdu, Sichuan 610083, P.R. China

Received September 20, 2017; Accepted July 10, 2018

DOI: 10.3892/ijo.2018.4533

Abstract. The aim of the present study was to evaluate the effects of resveratrol on small-cell lung cancer (SCLC) cell proliferation and apoptosis. The results demonstrated that resveratrol concentration- and time-dependently reduced H446 cell viability. In addition, cells treated with resveratrol displayed higher apoptotic rates, in association with mitochondrial depolarization, cytochrome c release from the mitochondrial compartment to the cytoplasm, apoptosis-inducing factor translocation from the mitochondrial compartment to the nucleus, and altered protein levels of Bcl-2, Bcl-xL and Bax. Furthermore, resveratrol promoted H446 cell inhibition by cisplatin, as reflected by reduced viability and increased apoptosis. These findings suggest that resveratrol exerts antitumor effects on SCLC H446 cells and promotes H446 cell killing by cisplatin via modulation of intrinsic apoptosis.

Introduction

Lung cancer, a very common type of cancer, has become the leading cause of cancer-related mortality worldwide (1). Approximately 15-20% of all lung carcinomas are categorized as small-cell lung cancer (SCLC), which is of neuroendocrine origin and is characterized by aggressiveness and high metastatic potential (2). Strikingly, >2/3 of SCLC cases are detected as advanced cancer with associated metastasis, with a 5-year survival rate as low as 5-10% (3). Cisplatin-based chemotherapy is the most commonly applied treatment for SCLC patients; however, it is not as effective as originally reported, due to the development of drug resistance. Therefore, methods that can enhance the effects of cisplatin and/or relieve pain in SCLC patients are urgently needed.

Resveratrol (Res; 3,4',5-trihydroxystilbene; C14H12O3) widely exists in grapes, berries, peanuts and wine, and possesses multiple confirmed therapeutic properties such as antioxidant, anti-inflammatory, anti-apoptotic and anticancer properties (4-9). Indeed, Res suppresses malignant cell growth and reduces the expression levels of cancer-related genes; in addition, it induces cell cycle arrest and apoptosis (10-13). More importantly, accumulating evidence suggests that Res promotes cancer cell apoptosis via Bcl-2 downregulation, Bax upregulation and activation of various caspases (13-16). Furthermore, Res alters mitochondrial function, redox state and mitochondrial synthesis (17). Previous studies have assessed the pharmacological effects of Res on NSCLC (18). However, only few studies have focused on its effects on SCLC.

Based on this evidence, it was hypothesized that Res stimulation may promote apoptosis of SCLC H446 cells by inducing mitochondrial dysfunction and regulating apoptotic factors. Therefore, the aim of the present study was to assess the pro-apoptotic effects of Res on H446 cells and investigate whether it promotes the inhibitory effects of cisplatin on SCLC cells and the underlying mechanism.

Materials and methods

Cell culture. SCLC H446 cells were provided by the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI-1640 containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Waltham, MA, USA) in a humidified environment with 5% CO2 at 37°C.

Growth inhibition assay. H446 cells in the logarithmic growth phase were seeded in 96-well plates and treated with Res at various concentrations for 24 h (n=8). The optimal Res concentration was further assessed at 12, 24 or 48 h (n=8). In addition, H446 cells were treated with Res and cisplatin simultaneously. After treatment, MTT (5 mg/ml, 15 µl/well) was added to each well and incubated for another 4 h. Then, the supernatant was replaced by 200 µl DMSO and absorbance was read at 492 nm on a Bio-Rad 550 microplate reader (Bio-Rad Laboratories, Shanghai, China).
Assessment of morphological alterations in cells. H446 cells were cultured in 24-well plates and treated as described above. Then, morphological changes in the cells were observed under a microscope (DMI6000B, Leica Microsystems GmbH, Wetzlar, Germany) at a magnification of x100. The effects of Res, cisplatin and Res/cisplatin combination on H446 cells were reflected by the morphological changes.

Flow-cytometric analysis of cellular apoptosis. Cellular apoptosis was measured using flow cytometry. In brief, H446 cells were collected after treatment with Res, cisplatin, or Res/cisplatin combination, and incubated with PI and Annexin V-FITC solution (BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer's instructions. Analysis was performed on a flow cytometer (BD Biosciences).

Measurement of intracellular reactive oxygen species (ROS) levels. In order to assess ROS level changes in cells treated with Res, cisplatin, or Res/cisplatin combination, H446 cells from each group were stained with 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA) and assessed with flow cytometry. The mean fluorescence intensity of DCF was considered to reflect the intracellular ROS level.

Mitochondrial membrane potential (MMP) assessment. In order to assess MMP alterations after treatment with different Res concentrations, H446 cells were stained with tetrachlorotetraethylbenzimidazol carbocyanine iodide (JC-10; Beyotime Institute of Biotechnology, Shanghai, China) for 45 min, and analyzed with a flow cytometer (BD Biosciences).

Western blotting. The cellular expression levels of the proteins of interest were measured by western blot analysis. Briefly, cytoplasmic, nuclear and total protein samples were extracted with specific protein extraction kits (BestBio Institute of Biotechnology, Wuhan, China). Total protein amounts in various fractions were quantified by the BCA assay with a commercially available kit (Keygen Institute of Biotechnology, Nanjing, China). Equal amounts of denatured protein (20 µg) were resolved by 12% SDS-PAGE and transferred onto PVDF membranes (EMD Millipore, Billerica, MA, USA). After blocking with 5% (w/v) non-fat milk, primary antibodies against apoptosis-inducing factor (AIF), Cyto-C, Bcl-2 and Bcl-xL (dilution, 1:2,000) were added for overnight incubation at 4°C. The membranes were subsequently incubated with secondary antibodies at room temperature for 2 h. Immunoreactive signals were revealed by the ECL detection system (ChemiScope 5300 Pro, CLiNX, Shanghai, China).

Statistical analysis. Experiments were repeated at least 3 times. Data are presented as mean ± standard deviation (SD). The GraphPad Prism program (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analyses. Treatment groups were compared by one-way analysis of variance followed by Dunnett's test, with P<0.05 considered statistically significant.

Results

Res inhibits SCLC cells. As shown in Fig. 1, Res suppressed the proliferation of H446 cells and the IC50 of H446 cells was ~35 µg/ml of Res. Cell proliferation suppression was observed in a concentration- (Fig. 1A) and time- (Fig. 1B) dependent manner, when assessed for 35 µg/ml at 12, 24 and 48 h, respectively. Therefore, Res at 35 µg/ml was used in subsequent experiments.

Treatment with Res leads to morphological changes in H446 cells. The morphological changes in H446 cells treated with Res were assessed. As shown in Fig. 1C and D, normal cells distributed throughout the microscopic field were found in the control group; the cell bodies were stretched into various directions, and the nucleus remained in the center of each cell surrounded by a relatively darker rim. Following treatment with Res (20, 30 and 40 µg/ml for 24 h, or 35 µg/ml for 12, 24 and 48 h), the cell
number was decreased to different extents, and the cells were not stretched as their control counterparts; in addition, different amounts of granular/refractory points were observed when the cells were treated with varied doses of Res, and the granular element increased in a dose-dependent manner.

Res stimulation promotes apoptosis of H446 cells. To further evaluate the anticancer properties of Res, H446 cells were treated with Res and apoptotic cells were detected as described above. The results (Fig. 2) demonstrated that Res treatment resulted in increased numbers of apoptotic H446 cells (P<0.05 vs. control group). Of note, apoptotic cells were markedly increased after 48 h of incubation with Res compared with the 24-h group (P<0.05).

Res treatment results in enhanced ROS generation in H446 cells. Res treatment resulted in increased intracellular ROS levels in H446 cells. Specifically, the results demonstrated increased ROS generation in H446 cells treated with 20 µg/ml Res for 24 h or 35 µg/ml Res for 6 h (both P<0.05 vs. control group); furthermore, time- and dose-dependent increases in ROS levels were observed in cells treated with 30 and 40 µg/ml Res for 24 h, or 35 µg/ml Res for 12 and 24 h (all P<0.05 vs. control cells) (Fig. 3).
Res treatment results in decreased MMP in H446 cells. Based on the findings mentioned above, the MMP was further evaluated in cells treated with various concentrations of Res for 24 h. While a few cells in the control group exhibited reduced MMP, significantly more cells with decreased MMP were found after treatment with 20 µg/ml Res (P<0.05 vs. control group); in addition, the number of cells with reduced MMP increased with the Res dose (P<0.05; Fig. 4A). Next, MMP changes were evaluated in H446 cells treated with 35 µg/ml Res at different times. The results demonstrated a significant decrease in MMP in H446 cells incubated with Res for 6 h (P<0.05 vs. control group); an even higher number of cells with reduced MMP were detected after treatment with 30 µg/ml Res for 12 or 24 h (all P<0.05; Fig. 4B).

Res treatment results in enhanced cytochrome c release and AIF translocation. To validate the critical function of mitochondria in Res-associated H446 cell apoptosis, cytochrome c release from the mitochondrial compartment to the cytoplasm and AIF translocation were assessed in H446 cells. As shown in Fig. 5, Res treatment resulted in increased cytochrome c content in the cytoplasm and AIF translocation from the mitochondria to the nucleus (P<0.05 vs. control group); in addition, a higher dose (30 or 40 µg/ml) of Res or prolonged treatment (12 or 24 h) markedly amplified these effects (P<0.05 vs. control group).

Res regulates apoptotic factors. Bcl-2, Bcl-xL and Bax are well-known contributors to the intrinsic apoptotic pathway; therefore, the amounts of Bcl-2, Bcl-xL and Bax proteins in H446 cells were assessed by immunoblotting. As shown in Fig. 6, Res downregulated Bcl-2 and Bcl-xL expression (P<0.05 vs. control group), with higher doses (30 or 40 µg/ml) or prolonged treatment (12 or 24 h) exacerbating these effects (all P<0.05). Furthermore, treatment with Res resulted in higher Bax levels in H446 cells (P<0.05 vs. control group), in a time- and dose-dependent manner (all P<0.05).

Res promotes cisplatin regulation of the mitochondrial apoptotic pathway. As shown above, Res enhanced the effects of cisplatin on H446 cells, including growth inhibition, ROS production and mitochondrial depolarization. Therefore, we further investigated whether Res also alters the effects of cisplatin on the mitochondrial apoptotic pathway. As shown in Fig. 9A and B, treatment with cisplatin (5 µg/ml) resulted in increased cytochrome c levels in the cytoplasm (P<0.05 vs. control group) and increased AIF translocation (P<0.05 vs. control group); furthermore, a markedly increased

Res enhances the effects of cisplatin on cell growth. Based on the findings mentioned above, indicating that Res inhibits proliferation while inducing apoptosis in H446 cells by regulating the mitochondrial pathway, the effects of Res in augmenting the antitumor effects of cisplatin were further evaluated. As shown in Fig. 7A, cisplatin dose-dependently inhibited H446 cell growth. Furthermore, treatment with 35 µg/ml Res or 5 µg/ml cisplatin markedly reduced H446 cell proliferation (P<0.05 vs. control group), and combined treatment with the two agents resulted in an even more marked growth suppression in H446 cells in comparison with cisplatin or Res monotherapy (all P<0.05; Fig. 7B).

Res treatment results in enhanced effects of cisplatin on ROS generation and mitochondrial depolarization. Next, we assessed how Res affects cisplatin-associated ROS production and MMP changes. As shown in Fig. 8, treatment with cisplatin (5 µg/ml) or Res (35 µg/ml) increased ROS generation, as well as the number of cells with decreased MMP (all P<0.05 vs. control group). In addition, combining both agents at the abovementioned concentrations further enhanced ROS production in H446 cells, as well as the number of cells with reduced MMP, compared with the monotherapy groups (all P<0.05). These findings suggested that Res enhanced the effects of cisplatin on ROS generation and mitochondrial depolarization in H446 cells.
Figure 5. Cytochrome c release from the mitochondria into the cytosol and AIF translocation from the mitochondria to the nucleus in H446 cells as detected by immunoblotting. (A and C) Treatment with 20, 30 and 40 µg/ml resveratrol (Res) for 24 h, or 35 µg/ml for 6, 12 or 24 h markedly increased the Cyto-C content in the cytosol (P<0.05 vs. control group; ""P<0.05 vs. "#P; "###P<0.05 vs. "##P), while it decreased the content of AIF ("*P<0.05 vs. control group; "**P<0.05 vs. "*P; "***P<0.05 vs. "**P). (B and D) Furthermore, 20, 30 and 40 µg/ml Res for 24 h, or 35 µg/ml for 6, 12 and 24 h significantly increased the content of AIF in the nucleus (P<0.05 vs. control group; ""P<0.05 vs. "P; "***P<0.05 vs. "**P).

Figure 6. Expression levels of apoptosis regulators in H446 cells treated with resveratrol (Res). The expression levels of various proteins were evaluated by immunoblotting. (A-D) Bcl-2, Bcl-xL and Bax levels in H446 cells treated with 0, 20, 30 and 40 µg/ml Res for 24 h. (E-H) Bcl-2, Bcl-xL and Bax levels in H446 cells treated with 35 µg/ml Res for 0, 3, 6, 12 or 24 h. Data are presented as the mean ± standard deviation of three separate experiments. '*'P<0.05 vs. control group; ""P<0.05 vs. "P; "***P<0.05 vs. "**P.
Figure 7. Combined treatment with cisplatin and resveratrol (Res) further inhibits H446 cell proliferation. Cell viability was measured by the MTT assay. (A) Cisplatin reduced H446 cell proliferation in a dose-dependent manner. (B) Res amplified the antitumor activity of cisplatin. *P<0.05 vs. control; **P<0.05 vs. *P.

Figure 8. Resveratrol (Res) enhances the effects of cisplatin on reactive oxygen species (ROS) generation and mitochondrial depolarization. (A-a-d) Representative flow cytometry diagrams for ROS production levels in cells treated with cisplatin, Res, and cisplatin + Res. (B-a-d) Representative flow cytometry diagrams for mitochondrial membrane potential (MMP) in cells treated with cisplatin, Res, and cisplatin + Res. Quantification of (Ae) ROS and (Be) MMP; data are presented as the mean ± standard deviation of three separate experiments. *P<0.05 vs. control; **P<0.05 vs. *P.

Figure 9. Resveratrol (Res) amplifies cisplatin-associated regulation of the mitochondrial apoptotic pathway and apoptosis regulators. Relative (A) apoptosis-inducing factor (AIF) and Cyto-C expression levels in the cytosol, and (B) AIF levels in the nucleus of H446 cells treated with cisplatin, Res, and cisplatin + Res. Cyto-C release into the cytosol and AIF translocation from the mitochondria to the nucleus were increased in H446 cells treated with cisplatin; in addition, combined treatment with cisplatin and Res amplified these effects. *P<0.05 vs. control; **P<0.05 vs. *P. (C-F) Expression levels of Bcl-2, Bcl-xL and Bax in H446 cells treated with cisplatin, Res, and cisplatin + Res; data are presented as the mean ± standard deviation of three separate experiments. *P<0.05 vs. control; **P<0.05 vs. *P; ***P<0.05 vs. **P.
cytochrome c release and AIF translocation were observed after combined treatment with cisplatin and Res (35 μg/ml) (all P<0.05). Next, the levels of the Bcl-2, Bcl-xl, and Bax proteins in H446 cells treated with cisplatin and/or Res were assessed by immunoblotting. As shown in Fig. 9C-F, treatment with Res or cisplatin downregulated Bcl-2 and Bcl-xl (P<0.05 vs. control group), while it upregulated Bax in H446 cells; these effects were further amplified in the combination group (all P<0.05).

Discussion

Cisplatin-based chemotherapy is effective as SCLC treatment, but it may also be intolerable to patients due to the side effects and development of drug resistance. Therefore, it is urgent to develop novel and efficient chemopreventive and chemotherapeutic drugs (19-21). Pharmacologically active ingredients from plants may be of great value for cancer patients, as they are generally associated with only moderate side effects. As one of such agents, Res exerts chemopreventive and chemotherapeutic effects in vitro and in vivo (13,22-24). Previous studies reported that Res enhances tumor cell sensitivity to chemotherapeutics (25), although the mechanism by which it sensitizes SCLC cells to cisplatin remains largely unknown. The aim of the present study was to evaluate the antitumor effects of Res on H446 cells and its impact on cisplatin-associated cancer inhibition.

As described above, Res concentration- and time-dependently reduced cell proliferation, with morphological alterations also reflecting its pro-apoptotic properties in the SCLC H446 cell line. ROS is both the trigger and the further inducing factor in apoptosis, which is closely related to mitochondrial dysfunction. It is well known that ROS play a key role in modulating cell apoptosis, and chemotherapeutic strategies are often aimed at altering the oxidation and antioxidation balance by increasing ROS generation, leading to permanent damage that subsequently results in tumor cell apoptosis (26). In the process of cell apoptosis, uncoupling oxidative phosphorylation occurs in the respiratory chain, ROS production increases in the cells, and excessive ROS production leads to reduced MMP (27), whereas pro-apoptotic factors, including cytochrome c and AIF, are released and trigger apoptosis (28,29). Cytochrome c release is closely regulated by the Bcl-2 family of proteins, which includes anti- and pro-apoptotic entities (30-33). It is widely accepted that Bcl-2 and Bcl-xl act in preventing apoptosis and blocking cell death caused by various stressors (34,35). By contrast, the Bax homodimer, which shares sequence homology with Bcl-2, is an important pro-apoptotic protein (36).

Previous studies have confirmed that high Res concentrations cause tumor regression, involving the mitochondrial intrinsic apoptotic pathway (37). In addition, it was suggested that Res-induced apoptosis may be mediated by Bcl-2 downregulation and Bax upregulation (15,16,38). The present study also demonstrated that Res enhanced ROS production and mitochondrial depolarization in H446 cells; specifically, Res decreased Bcl-2 and Bcl-xl expression, increased Bax levels, enhanced cytochrome c release and promoted mitochondrial-nuclear translocation of AIF, which jointly resulted in apoptosis.

Next, the viability of H446 cells treated with cisplatin, Res, or cisplatin/Res combination was assessed, and the combination was found to be markedly more effective in inhibiting H446 cells compared with either monotherapy. In addition, combined treatment with cisplatin and Res induced apoptosis in H446 cells at a higher rate compared with either monotherapy. Furthermore, MMP reduction, increased cytochrome c release and enhanced AIF translocation were all markedly amplified in the combination group compared with either monotherapy. Finally, combined treatment with cisplatin and Res resulted in sharper decrease of Bcl-2 and Bcl-xl levels and marked increase of Bax levels compared with the monotherapies.

In conclusion, the present study demonstrated that Res suppresses SCLC H446 cell growth and promotes apoptosis through the mitochondrial apoptotic pathway. Furthermore, Res may also enhance the antitumor effects of cisplatin, at least in part through the abovementioned mechanisms.

Acknowledgements

Not applicable.

Funding

This study was funded by the National Natural Science Foundation of China (grant no. 81071933).

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Availability of data and materials

All analyzed data are available from the corresponding author on reasonable request.

Authors’ contributions

WL and YS performed the experiments, which were designed and supervised by FJ and LM. RW and LP participated in data collection and analysis in this study.

Competing interests

The authors declare that they have no competing interests to disclose.

References